[1]韦思达,刘永军.奥妥珠单抗联合化疗治疗 初治滤泡性淋巴瘤的经济性评价 ——与利妥昔单抗联合化疗的比较[J].卫生经济研究,2022,39(11):45-50.
　WEI Sida,LIU Yongjun.Economic Evaluation of Otuzumab in combination with Chemotherapy for Primary Treatment of Follicular Lymphoma ——Comparison with Rituximab in Combination with Chemotherapy[J].Journal Press of Health Economics Research,2022,39(11):45-50.
点击复制

奥妥珠单抗联合化疗治疗 初治滤泡性淋巴瘤的经济性评价
——与利妥昔单抗联合化疗的比较
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年11期
页码:
45-50
栏目:
药械管理
出版日期:
2022-10-26

文章信息/Info

Title:
Economic Evaluation of Otuzumab in combination with Chemotherapy for Primary Treatment of Follicular Lymphoma
——Comparison with Rituximab in Combination with Chemotherapy
作者:
韦思达1; 刘永军1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
WEI Sida;  LIU Yongjun
School of International Pharmaceutical Business, China pharmaceutical Univercity, Nanjing Jiangsu 211198, China
关键词:
奥妥珠单抗; 利妥昔单抗; 滤泡性淋巴瘤; 成本-效用; 药物经济学评价
Keywords:
Otolizumab;  Rituximab;  Follicular lymphoma;  cost-utility;  pharmacoeconomic evaluation
分类号:
R95
文献标志码:
A
摘要:
目的：对奥妥珠单抗联合化疗（G-CHOP）和利妥昔单抗联合化疗（R-CHOP）治疗初治滤泡性淋巴瘤（FL）患者进行药物经济学评价。方法：采用动态Markov模型，对G-CHOP和R-CHOP治疗方案的成本-效用进行分析。结果：与R-CHOP相比，G-CHOP治疗FL患者32年可提高0.39个QALY，当奥妥珠单抗价格为初上市价格时，ICER为633 489元/QALY，不具有经济优势；当奥妥珠单抗实行新医保价格时，无论R-CHOP选用原研药还是生物类似药，G-CHOP均具有经济优势，经济优势的奥妥珠单抗价格临界值约为13 760元；R-CHOP若选用生物类似药可节省治疗成本约28 164元。结论：在目前新医保价格的情境下，G-CHOP治疗初治FL获得更多QALYs，ICER小于阈值，更具成本-效用优势。
Abstract:
Objective To conduct a pharmacoeconomic evaluation of otuzumab in combination with chemotherapy(G-CHOP) and rituximab in combination with chemotherapy (R-CHOP) for the treatment of patients with primary treatment follicular lymphoma (FL). Methods Cost-utility analyses of G-CHOP and R-CHOP treatment regimens were performed using a dynamic Markov model. Results Compared with R-CHOP, G-CHOP treated FL patients for 32 years by 0.39 QALYs, with an ICER of $633,489/QALY when the otuzumab price was the initial launch price, which was not economically advantageous. When the new health insurance price was implemented for otuzumab, G-CHOP was economically advantageous regardless of whether R-CHOP chose the original drug or a biosimilar. When the new health insurance price was implemented, G-CHOP had an economic advantage regardless of whether R-CHOP chose the original drug or a biosimilar, with the economic advantage of otuzumab at a price threshold of approximately RMB 13,760. R-CHOP could save approximately RMB 28,164 in treatment costs if it chose a biosimilar. Conclusion In the current context of new health insurance prices, G-CHOP has more cost-utility advantages in treating primary FL with more QALYs and a sub-threshold ICER.

参考文献/References:

[1] 中华医学会血液学分会，中国抗癌协会淋巴瘤专业委员会.中国滤泡性淋巴瘤诊断与治疗指南（2020年版）[J].中华血液学杂志，2020，41（7）：537-544.
[2] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）淋巴瘤诊疗指南2021[M].北京：人民卫生出版社，2021.
[3] Herter S,Herting F,Mundigl O,et al.Preclinical activity of the type II CD20 antibody GA101(obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models[J].Mol Cancer Ther,2013,12(10):2031-2042.
[4] M?觟ssner E,Brünker P,Moser S,et al.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity[J].Blood,2010 ,115(22):4393-4402.
[5] 淋巴瘤之家.2020中国滤泡性淋巴瘤患者生存状况白皮书[EB/OL].（2020-12）[2022-03-22].https://www.house086.com/thread-191666-1-1.html.
[6] 淋巴瘤之家.2019淋巴瘤患者生存状况白皮书[EB/OL].（2019-09）[2022-03-22].https://www.house086.com/forum.php?mod=viewthrea d&tid=159226&highlight.
[7] Marcus R,Davies A,Ando K,et al.Obinutuzumab for the First-Line Treatment of follicular lymphoma[J].N Engl J Med,2017,377(14):1331-1344.
[8] 中国临床肿瘤学会（CSCO）淋巴瘤专家委员会.奥妥珠单抗临床用药指导原则中国专家共识（2021年版）[J].白血病·淋巴瘤，2021，30（10）：581-587.
[9]刘国恩.中国药物经济学评价指南：2020[M].北京：中国市场出版社，2020：27-28.
[10] William Townsend,Christian Buske,Guillaume Cartron,et al.Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma:Updated results from the phase III Gallium Study[J].Journal of Clinical Oncology，2020，38，15_suppl：8023.
[11] 国家统计局人口和就业统计司.中国人口和就业统计年鉴2019 [M].北京：中国统计出版社，2019.
[12] 周挺，马爱霞.生存分析在药物经济学评价Markov模型转移概率计算中的应用[J].中国循证医学杂志，2018，18（10）：1129-1134.
[13] Wild D,Walker M,Pettengell R,et al.PCN62 Utility Elicitation in patients with follicular lymphoma[J].Value Health,2006,9:A294.
[14] 刘国强，康朔.阿替利珠单抗联合标准化疗方案治疗广泛期小细胞肺癌的成本-效用分析[J].中国药房，2021，32（1）：77-81.
[15] 张伟，王研，丁年羊，等.长、短效重组人粒细胞刺激因子对恶性肿瘤患者白细胞减少症的有效性及经济性分析[J].肿瘤药学，2018，8（5）：811-814.
[16] Wang H,Huang L,Gao P,et al.Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial[J].BMJ Open,2020, 10(2):e030738.
[17] Wang X J,Wong M,Hsu L Y,et al.Costs associated with febrile neutropenia in solid tumor and lymphoma patients-an observational study in Singapore[J].BMC Health Serv Res,2014,14:434.
[18] Kasi P M,Tawbi H A,Oddis C V,et al.Clinical review:Serious adverse events associated with the use of rituximab-a critical care perspective[J].Crit Care,2012,16(4):231.
[19] 中国国家药品监督管理局.奥妥珠单抗注射液说明书[EB/OL].[2021-06-01].https://www.cde.org.cn/main/xxgk/postmarketpage? acceptidCODE=3cb63c46a31a1c1e574e1fa2fa2aba58.

更新日期/Last Update: 2022-10-26